𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II evaluation of paclitaxel, α-interferon, and cis-retinoic acid in advanced renal cell carcinoma

✍ Scribed by Ulka Vaishampayan; Lawrence Flaherty; Wei Du; Maha Hussain

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
71 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II pilot trial of 13-cis retinoi
A Phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma
✍ Felix H. Brembeck; Klaus Schoppmeyer; Ursula Leupold; Costel Gornistu; Volker Ke 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## BACKGROUND. Advanced unresectable pancreatic adenocarcinoma has a dismal prognosis. The authors previously have shown that retinoic acid (RA) and interferon-␣ (IFN-␣) inhibit growth and induce differentiation in human pancreatic carcinoma cells in vitro and in vivo. The purpose of this trial wa

Phase II clinical trial of 13-cis-retino
Phase II clinical trial of 13-cis-retinoic acid and interferon-α-2a in patients with advanced esophageal carcinoma
✍ Peter C. Enzinger; David H. Ilson; Leonard B. Saltz; Lisa K. Martin; David P. Ke 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

## BACKGROUND. Interferon in combination with 5-fluorouracil has been shown to be active in squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus. 13-cis-retinoic acid (CRA) has chemopreventive activity in SCC of the head and neck, and, in combination with interferon, has antitumo

13-CIS retinoic acid and interferon-α ±
13-CIS retinoic acid and interferon-α ± irradiation in the treatment of squamous-cell carcinomas
✍ Wolfgang Hoffmann; Martina Schiebe; Peter Hirnle; Rainer Souchon; Michael Clemen 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 43 KB

Pre-clinical data indicate that retinoid/interferon combinations have significant activity in modulating malignant cell growth, differentiation and programmed cell death in different hematologic and solid tumor systems . Clinically, the combination of 13-cis retinoic acid (13cRA) and interferon-a (I

A phase II trial of interferon-α and 5-f
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested